SHANGHAI, China, Dec. 22, 2020 (GLOBE NEWSWIRE) — Everest Medicines, a biopharmaceutical firm targeted on creating and commercializing transformative pharmaceutical merchandise that handle important unmet medical wants for sufferers in Higher China and different elements of Asia, introduced in the present day the appointment of Lan Kang to the Firm’s Board of Administrators as a non-executive director. Ms. Kang has greater than twenty years of expertise within the life sciences business with important experience constructing and main key enterprise improvement and operations capabilities at world firms.
“Ms. Kang’s broad company management and monitor file of success as a life sciences enterprise chief can be invaluable to Everest Medicines because the Firm continues to advance its sturdy portfolio of novel, clinical-stage drug candidates and concurrently grows its place as the worldwide chief in addressing important unmet medical wants in Higher China and different rising Asia Pacific markets,” mentioned Wei Fu, Chairman of Everest Medicines and Chief Government Officer of CBC Group.
“I’m excited to affix this achieved and dedicated staff of business leaders as we work collectively to attach and speed up world pharmaceutical innovation for Chinese language sufferers and convey a broad vary of novel therapies to the area,” mentioned Ms. Kang.
Ms. Kang has served at Fosun in a number of roles, together with as Government Board Director and Senior Vice President of Fosun Worldwide, the place she was liable for Fosun’s insurance coverage enterprise, in addition to chief HR officer. She has additionally held the function of non-executive Board Director at quite a few healthcare associated firms, together with Fosun Pharma and Fosun United Well being Insurance coverage. Previous to becoming a member of Fosun, Ms. Kang spent 5 years at McKinsey & Firm in China, along with working as an oncology analysis scientist in her early profession. At present, Ms. Kang serves as a managing director at C-Bridge Worth Creation Restricted of CBC Group.
Ms. Kang obtained her Bachelor’s diploma in Organic Science and Expertise from Zhejiang College in China, in addition to a MBA diploma in Healthcare Administration with honors from The Wharton College of the College of Pennsylvania and a Grasp’s diploma in Biochemistry from Tulane College in Louisiana within the US.
About Everest Medicines
Everest Medicines is a biopharmaceutical firm targeted on creating and commercializing transformative pharmaceutical merchandise that handle important unmet medical wants for sufferers in Higher China and different Asian markets. The administration staff of Everest Medicines has deep experience and an in depth monitor file of high-quality scientific improvement, regulatory affairs, CMC, enterprise improvement and operations each in China and with main world pharmaceutical firms. Everest Medicines has constructed a portfolio of eight doubtlessly world first-in-class or best-in-class molecules, lots of that are in late stage scientific improvement. The Firm’s therapeutic areas of curiosity embody oncology, autoimmune issues, cardio-renal illnesses and infectious illnesses. For extra data, please go to its web site at www.everestmedicines.com.
For additional data, please contact:
Media in US and Europe:
Media in China:
+86 (10) 6583-7510